Tandem Diabetes Care, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Tandem Diabetes Care is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $17.15, 39.3% below its 52-week high and below its 200-day average, which is falling.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More about the company

$17.15

+4.89% today

$1.2B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TNDM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 25w

S4 14w

S2 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 5w → S4 12w → S1 8w → S2 25w → S3 6w → S2 4w → S3 4w → S4 9w → S1 7w → S4 13w → S1 6w → S4 14w → S1 7w → S2 21w → S3 4w → S4 9w → S1 7w → S2 2w → S3 1w → S4 1w current

Total tracked: 165 weeks across 20 stage runs.

TNDM among Medical Devices37th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…37	TNDMTandem Diabetes Care, Inc.	Stage 4 · wk 2	63	+4.7%

vs 52W High

-39.3%

$12.82 lo$28.26 hi

39.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-9.8%

200 DMA: $19.01 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.98x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+4.7%

+0.2%

-17.1%

YTD

-20.4%

+11.4%

Scan Membership

Breakout Watch

Latest: 2024-09-19

9 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.98x

2026-10-21S4

Wk 2 · Vol 0.57x

2026-10-20S4

Wk 2 · Vol 0.82x

2026-10-19S4

Wk 1 · Vol 0.63x

2026-10-16S4

Wk 1 · Vol 0.79x

2026-10-15S4

Wk 1 · Vol 2.24x

2026-10-14S4

Wk 1 · Vol 1.08x

2026-10-13S43→4

Wk 1 · Vol 0.82x

2026-10-12S32→3

Wk 1 · Vol 0.75x

2026-10-09S2

Wk 3 · Vol 0.68x

2026-10-08S2

Wk 3 · Vol 1.39x

2026-10-07S2

Wk 3 · Vol 1.09x

Moving averages & range

50 DMA

$18.50

200 DMA

$19.01

52W High

$28.26

52W Low

$12.82

5D Low

$16.24

Resistance levels (recent highs)

20d High

$17.15

60d High

$23.73

120d High

$23.73

250d High

$28.26

Next resistance

+38.4%

to 60d High

ROE

-48.0%

Profit margin -6.1%

Dividend Yield

0.00%

P/B 9.1

Tandem Diabetes Care: quick answers

What stage is Tandem Diabetes Care in?

As of Oct 22, 2026, Tandem Diabetes Care (TNDM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Tandem Diabetes Care in an uptrend?

No. Tandem Diabetes Care is in a Stage 4 downtrend. It trades 9.8% below its 200-day average, which is falling.

How far is Tandem Diabetes Care from its 52-week high?

Tandem Diabetes Care closed at $17.15 on Oct 22, 2026, 39.3% below its 52-week high of $28.26. Its 52-week low is $12.82.

How has Tandem Diabetes Care performed over the past year?

As of Oct 22, 2026, Tandem Diabetes Care is up 11.4% over the past year and down 20.4% so far in 2026.

Which sector and industry is Tandem Diabetes Care in?

Tandem Diabetes Care is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.